Yale University, New Haven, CT.
University of Iowa Hospitals and Clinics, Iowa City, IA.
Chest. 2022 Mar;161(3):614-628. doi: 10.1016/j.chest.2021.10.044. Epub 2021 Nov 10.
Bronchial thermoplasty is a device-based treatment for subjects ≥ 18 years of age with severe asthma poorly controlled with inhaled corticosteroids and long-acting beta-agonists. The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study collected data on patients with severe asthma undergoing this procedure.
What are the 5-year efficacy and safety results in patients with severe asthma who have undergone bronchial thermoplasty?
This was a prospective, open-label, observational, multicenter study conducted in the United States and Canada. Subjects 18 to 65 years of age who were taking inhaled corticosteroids ≥ 1,000 μg/d (beclomethasone or equivalent) and long-acting beta-agonists ≥ 80 μg/d (salmeterol or equivalent) were included. Severe exacerbations, hospitalization, ED visits, and medication usage were evaluated for the 12 months prior to and at years 1 through 5 posttreatment. Spirometry was evaluated at baseline and at years 1 through 5 posttreatment.
A total of 284 subjects were enrolled at 27 centers; 227 subjects (80%) completed 5 years of follow-up. By year 5 posttreatment, the proportion of subjects with severe exacerbations, ED visits, and hospitalizations was 42.7%, 7.9%, and 4.8%, respectively, compared with 77.8%, 29.4%, and 16.1% in the 12 months prior to treatment. The proportion of subjects on maintenance oral corticosteroids decreased from 19.4% at baseline to 9.7% at 5 years. Analyses of subgroups based on baseline clinical and biomarker characteristics revealed a statistically significant clinical improvement among all subgroups.
Five years after treatment, subjects experienced decreases in severe exacerbations, hospitalizations, ED visits, and corticosteroid exposure. All subgroups demonstrated clinically significant improvement, suggesting that bronchial thermoplasty improves asthma control in different asthma phenotypes.
ClinicalTrials.gov; No.: NCT01350336; URL: www.
gov.
支气管热成形术是一种针对 18 岁及以上、吸入皮质类固醇和长效β-激动剂治疗控制不佳的严重哮喘患者的设备治疗方法。美国食品药品监督管理局(FDA)批准后评估支气管热成形术治疗严重持续性哮喘的临床试验(PAS2)收集了接受该手术的严重哮喘患者的数据。
接受支气管热成形术治疗的严重哮喘患者的 5 年疗效和安全性结果如何?
这是一项在美国和加拿大进行的前瞻性、开放标签、观察性、多中心研究。纳入年龄在 18 至 65 岁之间、每日吸入皮质类固醇≥1000μg(倍氯米松或等效物)和每日长效β-激动剂≥80μg(沙美特罗或等效物)的患者。在治疗前 12 个月和治疗后 1 至 5 年评估严重恶化、住院、急诊就诊和药物使用情况。在治疗前和治疗后 1 至 5 年评估肺活量。
共有 284 名患者在 27 个中心入组;227 名患者(80%)完成了 5 年随访。与治疗前 12 个月相比,治疗后 5 年时,严重恶化、急诊就诊和住院的患者比例分别为 42.7%、7.9%和 4.8%,而治疗前 12 个月分别为 77.8%、29.4%和 16.1%。维持口服皮质类固醇的患者比例从基线时的 19.4%降至 5 年时的 9.7%。基于基线临床和生物标志物特征的亚组分析显示,所有亚组均有统计学显著的临床改善。
治疗 5 年后,患者严重恶化、住院、急诊就诊和皮质类固醇暴露减少。所有亚组均表现出临床显著改善,表明支气管热成形术可改善不同哮喘表型的哮喘控制。
ClinicalTrials.gov;编号:NCT01350336;网址:www.clinicaltrials.gov。